Personalized Medicine Breakthrough: Mutations in * * FBXW7* * and * * SMAD4* * Predict Clinical Outcome in Metastatic Colorectal Cancer

Strategic Insights -

A new study published in the journal Cancers has made a significant breakthrough in personalized medicine, identifying mutations in * * FBXW7* * and * * SMAD4* * as predictors of clinical outcome in metastatic colorectal cancer. The research, conducted by a team of scientists from the University of Barcelona, used next-generation sequencing (NGS) to analyze the genetic profiles of 294 metastatic colorectal cancer tumors.

The study found that mutations in * * FBXW7* * and * * SMAD4* * were associated with a worse clinical outcome, with patients carrying these mutations being more likely to experience death. The researchers also discovered that concurrent mutations in * * TP53* * and * * FBXW7* * were associated with an increased risk of death. Analysis of the MSK-IMPACT mCRC cohort (N = 1095 patients) confirmed the same prognostic trend for the previously identified mutated genes.

The study's findings have significant implications for personalized medicine, highlighting the importance of considering the mutational status of * * FBXW7* * and * * SMAD4* * in addition to clinical factors when determining the prognosis of metastatic colorectal cancer patients. The researchers conclude that "gene set enrichment analysis revealed specific molecular pathways associated with * * SMAD4* * and * * FBXW7* * mutations in * * TP53* * -defficient tumors."

Key Takeaways:

  • Mutations in * * FBXW7* * and * * SMAD4* * were associated with a worse clinical outcome in metastatic colorectal cancer patients.
  • Concurrent mutations in * * TP53* * and * * FBXW7* * were associated with an increased risk of death.
  • Analysis of the MSK-IMPACT mCRC cohort (N = 1095 patients) confirmed the same prognostic trend for the previously identified mutated genes.
  • Gene set enrichment analysis revealed specific molecular pathways associated with * * SMAD4* * and * * FBXW7* * mutations in * * TP53* * -defficient tumors.
  • The study highlights the importance of considering the mutational status of * * FBXW7* * and * * SMAD4* * in addition to clinical factors when determining the prognosis of metastatic colorectal cancer patients.

Statistics:

  • The study analyzed 294 metastatic colorectal cancer tumors using next-generation sequencing (NGS).
  • Mutations in * * FBXW7* * were found in 9.5% of the tumors.
  • Mutations in * * SMAD4* * were found in 14% of the tumors.
  • Concurrent mutations in * * TP53* * and * * FBXW7* * were associated with an increased risk of death (p = 0.02; HR, 3.31).
  • The analysis of the MSK-IMPACT mCRC cohort (N = 1095 patients) confirmed the same prognostic trend for the previously identified mutated genes.
  • Gene set enrichment analysis revealed specific molecular pathways associated with * * SMAD4* * and * * FBXW7* * mutations in * * TP53* * -defficient tumors.

Sources:

  • Mutational Status of * * SMAD4* * and * * FBXW7* * Affects Clinical Outcome in * * TP53* * -Mutated Metastatic Colorectal Cancer. Cancers, 2022,14(5921):5921. (Cancers - http://www.mdpi.com/journal/cancers/).
  • NewsRx. Research from University of Barcelona Yields New Study Findings on Personalized Medicine (Mutational Status of * * SMAD4* * and * * FBXW7* * Affects Clinical Outcome in * * TP53* * -Mutated Metastatic Colorectal Cancer). Health & Medicine Week. December 30, 2022; p 5149.